OSMR and neoplasm: One gene that is likely to drive selection of 5p gain is the oncostatin-M receptor (OSMR; located at 5p13.1), which is commonly up-regulated in cervical SCC and produces a significantly worse clinical outcome when over-expressed, independent of tumour stage 4.